Review article: current and future treatment approaches for IBS with constipation

Joy J. Liu, Darren M. Brenner*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


Background: Multiple efficacious therapies are currently available for treating irritable bowel syndrome with constipation (IBS-C). IBS-C specific survey tools that assess symptom relief, treatment satisfaction, and quality of life are important for gauging real-world effectiveness. Aims/Methods: This article reviews clinical trial efficacy data as well as survey data on adequate relief and quality of life from pivotal trials for lubiprostone, linaclotide, plecanatide, tenapanor, and tegaserod. A brief discussion of agents in development with novel mechanisms of action is also provided. Results/Conclusions: Quality of life and symptom metrics should be standardized and continue to be represented in future IBS-C trials. The choice of agent should be tailored to probability of improving symptoms, safety, tolerability, and cost.

Original languageEnglish (US)
Pages (from-to)S53-S62
JournalAlimentary Pharmacology and Therapeutics
Issue numberS1
StatePublished - Dec 2021

ASJC Scopus subject areas

  • Gastroenterology
  • Pharmacology (medical)
  • Hepatology


Dive into the research topics of 'Review article: current and future treatment approaches for IBS with constipation'. Together they form a unique fingerprint.

Cite this